The expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and its role in corpora lutea (CL) function were studied in pseudopregnant rabbits. Corpora lutea were collected at an early stage (Day 4), midstage (Day 9), and late stage (Day 13) of pseudopregnancy. Immunohistochemistry found evidence for the presence of PPARgamma in the perinuclear cytoplasm and nucleus of all the luteal cells; immunoreactivity decreased from the early to the late stage, with immunonegativity of the nuclei of late stage CL. PPARgamma mRNA transcript was expressed in all the luteal stages with the lowest level in the late stage. In CL cultured in vitro, the PPARgamma agonist (15-deoxy delta12,14 prostaglandin J2 [15d-PGJ2], 200 nM) increased and the antagonist (T0070907, 50 nM) decreased progesterone secretion at early and midluteal stages, whereas 15d-PGJ2 reduced and T0070907 increased PGF2alpha at the same stages. Prostaglandin-endoperoxide synthase 2 (PTGS2) activity was reduced by 15d-PGJ2 and increased by T0070907 in CL of early and midluteal stages. Conversely, 15d-PGJ2 increased and T0070907 reduced 3beta-hydroxysteroid dehydrogenase (3beta-HSD) activity in early and midluteal stage CL. PGE2 in vitro secretion as well as PTGS1 and 20alpha-HSD enzymatic activities were not affected by 15d-PGJ2 and T0070907 in any CL types. These results indicate that PPARgamma plays a luteotropic role in pseudopregnant rabbits, through PTGS2 down-regulation and 3beta-HSD up-regulation, with a consequent PGF2alpha decrease and progesterone increase.
INTRODUCTION
The peroxisome proliferator-activated receptors (PPARs), a family of three (a, d, and c) nuclear receptor/transcription factors, are involved in several processes such as steroidogenesis, angiogenesis, tissue remodeling, cell cycle, and apoptosis [1] . These processes are critical for normal ovarian function [2] , and all three PPARs have been identified in the ovary of many species [3] . In particular, these nuclear receptors have been localized in the ovary of the rat [2, 4] , mouse [5] , pig [6] , sheep [7] , cow [8] [9] [10] , rabbit [11] , and human [12, 13] . Several in vitro studies have shown that PPAR agonists present contradictory actions on granulosa and luteal steroid secretion, depending on the species [1] . PPAR mechanisms in ovarian functions are not fully understood. However, comparisons with other cell models suggest that PPARs may regulate the genes required for follicle and corpora lutea (CL) maintenance [1] .
It is widely accepted that prostaglandins (PGs) play a key role in regulating CL function and life span [14] . While PGF2a is the main luteolytic factor, PGE2 is an important luteoprotective factor with luteotrophic or antiluteolytic actions [15] [16] [17] . The critical step in PG biosynthesis is the enzymatic conversion of arachidonic acid (AA) into PGH2 by prostaglandin-endoperoxide synthase 1 (PTGS1) or PTGS2. PGH2, in turn, is converted into four structurally active PGs (PGE2, PGF2a, PGD2, and PGI2) via specific PG synthases [18] . However, the biosynthesis of PGF2a is peculiar because it derives from three different pathways catalyzed by corresponding ketoreductases using PGH2, PGD2, or PGE2 as substrates. In many species, the CL themselves synthesize PGF2a and PGE2, whose production is regulated by a large array of local and systemic factors, suggesting a paracrine and autocrine role for these two PGs [19] [20] [21] [22] .
In cardiac myocytes and in prostate cells, PPARc was found to down-regulate the genes encoding PTGS2 [23] , an enzyme implicated in the control of ovulation and CL life span [16] . Current research is devoting considerable attention to PGD2 and PPAR; in fact, an initial screening of AA metabolites revealed that a dehydration product of PGD2, namely the cyclopentanone PG, 15-deoxy delta12,14 prostaglandin J2 (15d-PGJ2), is a potent PPARc ligand [2, 24] . A-series cyclopentanone PGs (PGAs) are dehydration products of PGE2 and can bind and activate PPARd or PPARc. PGAs are not considered a major product in the body but, conceivably, may be present in sites where PGE2 is produced [25] . PGF2a shows no binding to or activation of PPARs; however, PGF2a does indirectly inhibit PPARc activity by mediating its phosphorylation [25] .
The rabbit CL is a good model for investigating PPARc mechanisms that regulate luteal function because in this species it is possible to induce pseudopregnancy by exogenous gonadotropin-releasing hormone (GNRH) administration [26] .
Therefore, the main objective of the present study was to examine the modulatory effects of PPARc on rabbit CL during early, mid-, and late luteal stages of pseudopregnancy. With this end in view, experiments were devised to clarify the immunopresence and the gene expression of PPARc, as well as its effects in vitro on the production of progesterone, PGE2, and PGF2a, and on the activity of the enzymes involved in the regulation of CL life span: 3b-hydroxysteroid dehydrogenase (3b-HSD), 20a-HSD, PTGS1, PTGS2, and PGE2-9-ketoreductase (PGE2-9-K).
MATERIALS AND METHODS

Reagents and Hormones
Mouse monoclonal anti-PPARc (sc-7273) and anti-3b-HSD primary antibodies (sc-100466) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Biotin goat anti-mouse immunoglobulin G (IgG) secondary antibody, avidin-biotin complex (ABC, Vector Elite Kit), mouse IgG, and the chromogen 3,3 0 -diaminobenzidine tetrachloride (DAB) were obtained from Vector Laboratories (Burlingame, CA). The endogenous PPARc agonist 15d-PGJ2 and the selective antagonist T0070907 (.800-fold selectivity for PPARc over-PPARa and PPARd) [27] were purchased from Tocris Bioscience (Bristol, U.K.).
Random hexamer primers, deoxyribonuclease I (DNAase I amplification grade), RNAse H-reverse transcriptase (Superscript III Reverse Transciptase), Escherichia coli RNase H, DNA ladders, the reagent for the isolation and purification of total RNA (TRIzol), Taq DNA polymerase (Platinum), RNAsefree tubes and water, and deoxynucleotide monophosphates were obtained from Invitrogen (Milan, Italy). Primers for 18S rRNA and the corresponding competimers (QuantumRNA 18S internal standards) and PPARc were also acquired from Invitrogen. Tritiated hormones and AA were purchased from Amersham Biosciences (Little Chalfont, Bucks, U.K.), while progesterone, PGF2a, and PGE2 antisera, and nonradioactive hormones (NS-398, trilostane, and R-flurbiprofen) came from Sigma (St. Louis, MO).
Incubation wells were obtained from Becton Dickinson Co. (Clifton, NJ), while medium 199 and Earle Balanced Salt Solution were from GIBCO (Grand Island, NY). HEPES and bovine serum albumin (BSA) were purchased from Sigma, whereas all other pure grade chemicals and reagents were obtained locally.
The following hormonal preparations were administered via intramuscular injection: equine chorionic gonadotropin (Folligon; Intervet, Milan, Italy) and GNRH analog (Buserelin; Receptal. Hoechst-Roussel Vet, Milan, Italy). Protein concentration was determined by Bio-Rad Protein Assay Kit (Hercules, CA).
Animals and Hormonal Regimen
Sexually mature New Zealand white female rabbits (Oryctolagus cuniculus, 3.5-4 kg body weight, and 5 mo of age), were raised n premises owned by the University of Perugia and were used for all the experiments. The rabbits were housed individually in wire mesh cages under controlled light (14L:10D; lights off at 2100 h) and temperature (188C-248C) conditions. Each animal had free access to food and water. Pseudopregnancy was induced with 20 international units eCG followed 3 days later by 0.8 lg Buserelin [26] . The day of Buserelin injection was designated as Day 0. At Days 4 (early stage), 9 (midstage), and 13 (late stage) of pseudopregnancy, animals (n ¼ 6 for each luteal stage) were euthanized by cervical dislocation in compliance with the guidelines of the Italian Ministry of Health (the national laws on animal research, DL 116/92) and the European Communities Council directive on animal research (N. 86/ 609/EEC). The protocols involving the use of the animals for these experiments were approved by the Bioethic Committee of the University of Perugia.
Tissue Collection and Processing
Upon euthanasia, the reproductive tracts were promptly removed and thoroughly washed with saline. Within a few minutes, all the CL were excised from ovaries (;12 CL/ovary), and after careful dissection of nonluteal tissue by fine forceps under stereoscopic magnification, some were immediately processed for in vitro experiments while others were rinsed with RNAse-free PBS and frozen at À808C for later evaluation of gene expression. For the immunohistochemical detection of PPARc, the ovaries of two additional animals for each luteal stage were fixed by immersion in 4% (w/v) formaldehyde in PBS (pH 7.4) for 24 h at room temperature and subsequently processed for embedding in paraffin following routine tissue preparation procedures [28] .
Immunohistochemistry
Immunohistochemical investigation was performed according to procedures previously described [29, 30] . Slides were deparaffinized, rehydrated through graded concentrations of alcohol to distilled water, and submitted to antigen retrieval by microwaving in Tris solution (0.01 M, pH 8.5) at high power for 10 min. The slides were then cooled to room temperature. After rinsing with TBS (Tris-buffered saline), they were dipped in 3% H 2 O 2 in methanol for 1 h to quench the endogenous peroxidase activity and rinsed in TBS (100 mM Tris, 75 mM NaCl; pH 7.4). Background labeling was prevented by incubating the sections with normal goat serum diluted 1:10 for 1 h at room temperature. The slides were then incubated overnight at 48C in a moist chamber with the antiPPARc and anti-3b-HSD primary antibodies diluted 1:50 in TBS containing 0.2% Triton X-100 and 0.1% BSA. The next day, the slides were rinsed in TBS, treated again with normal goat serum and incubated with biotin goat antimouse secondary antibody diluted 1:200 for 30 min at room temperature. After TBS washes, the slides were exposed to the ABC kit for 30 min and rinsed again with TBS. The peroxidase activity sites were visualized using the DAB kit as the chromogen; the sections were rinsed with distilled water, washed in running tap water, dehydrated by passing through graded ethanol (70%, 95%, and 100% vol/vol) solutions, cleared in xylene, and, finally, mounted with Eukitt medium for light microscopy. Tissue sections in which the primary antibody was omitted or substituted by mouse IgG were used as negative controls of nonspecific staining. The intensity of immunostaining was assessed and compared microdensitometrically as previously described [31] using an image analysis system (IAAS 2000 image analyzer, Delta Sistemi, Rome, Italy).
RT-PCR
Total RNA was extracted from CL of three rabbits for each luteal stage as previously described [17] . Total RNA (5 lg) were reverse transcribed in 20 ll of SuperScript III Reverse Transcriptase cDNA synthesis mix using random hexamer according to the protocol provided by the manufacturer. Genomic DNA contamination was checked by developing the PCR without reverse transcriptase. Multiplex PCR amplification was carried out as previously described [17] using 1 ll of luteal cDNA as the template for the target (Table 1) and 18S primers. Cycling conditions consisted of an initial denaturizing cycle at 948C for 75 sec, followed by 35 cycles for each target gene at 948C for 15 sec, 608C for 30 sec, 728C for 45 sec, and a final extension step at 728C for 10 min. Within each experiment, the complete set of samples was processed in parallel in a single PCR, using aliquots of the same PCR master mix. The amplified PCR-generated products (20 ll of 25 ll total reaction volume) were analyzed by electrophoresis on 2% agarose gel using ethidium bromide staining. Analysis of amplification products was carried out as reported elsewhere [17] . The amplified products, collected from agarose gel after electrophoresis, were purified with Nucleospin Extract II kit, and their identities were confirmed by DNA sequencing using the Sanger method.
In Vitro Experiments
A method previously reported was used for the in vitro study [32, 33] . Early, mid-, or late stage CL were randomly distributed into incubation wells in 1 ml of culture medium 199 with Earle Balanced Salt Solution containing 2.2 mg/ml sodium bicarbonate, 2.3mg/ml HEPES, and 3% BSA (w/v). Before the treatment, the CL were quartered inside each well (one quartered CL/well) using fine forceps. Each set of incubation wells was divided into three experimental groups, each formed of five wells as follows: (I) medium alone as control, (II) PPARc agonist (15d-PGJ2, 200 nM), and (III) PPARc antagonist (T0070907, 50 nM). The culture plates were incubated at 378C in air with 5% CO 2 . The media of each well were collected after 4 h of incubation and stored ZERANI ET AL.
immediately at À208C for later determination of progesterone, PGF2a, and PGE2 well concentrations. Corpora lutea pieces were weighed and protein concentration was determined by an assay kit. Preliminary evidence led to our choice of the incubation conditions and the minimum effective dose for PPARc agonist and antagonist used in the present in vitro study (Fig. 1) .
Hormone Determination
Progesterone, PGF2a, and PGE2 concentrations were determined following the radioimmunoassay (RIA) protocols previously reported [32] . Intra-and interassay coefficients of variation and minimum detectable doses were: progesterone, 6.1%, 8.9%, and 11 pg/tube; PGF2a, 7.5%, 12.4%, and 18 pg/ tube; and PGE2, 6.4%, 12.2%, and 16 pg/tube.
Enzyme Activity Determination
The activities of PTGS1 and PTGS2 were determined by measuring the disappearance of the radiolabeled substrate [ 3 H] AA using a method previously reported [21, 34] . A selective PTGS2 inhibitor (NS-398, 1 lM) and nonselective PTGS inhibitor (acetylsalicylic acid, 1 mM) were used. For each sample, PTGS1 activity was determined by calculating the rate of loss of [ [21] .
The activity of 3b-HSD was determined by measuring the conversion of 3 H] pregnenolone and NADPH (3 mg/ml) were added to the incubation tube. The mixture was incubated at 378C for 10 min. Termination was achieved by the addition of 100 ll 0.1 M HCl. Steroids were extracted with diethyl ether and resuspended with 500 ml RIA buffer (74.5 mM Na 2 HPO 4 , 12.5 mM sodium EDTA, 0.1% gelatin, pH 7.5). Two hundred microliters RIA buffer containing progesterone-specific antiserum were added to duplicate samples, and the 
Statistical Analysis
All the data were examined by Levene test, which showed statistically significant homoscedasticity for all of the variables. Data were analyzed using two-way ANOVA (treatments vs. CL stages, Table 2 ) followed by StudentNewman-Keuls t-test. Differences were considered significant at P , 0.01.
RESULTS
Immunohistochemistry
Intense PPARc immunoreactivity was localized in the perinuclear cytoplasm and, with lesser intensity, in the nucleus of all the luteal cells at the early stage of pseudopregnancy (Fig. 2, A and B) . The density of immune reactive cells decreased (P , 0.01) from the early to late stage (Fig. 2, C , D, and G); in particular, the majority of the luteal cell nuclei were immunonegative at the late stage (Fig. 2D) . The wall of blood vessels (endothelial, stromal, and smooth muscle cells) was always negative (Fig. 2E) . No staining was detectable in negative control rabbit CL in which the primary antibody was omitted or substituted with mouse IgG (Fig. 2F) .
Expression of mRNA for Luteal PPARc
PPARc transcript was expressed in CL at different stages of pseudopregnancy with the lowest abundance (P , 0.01) at the late stage of pseudopregnancy (Fig. 3, upper panel) .
In Vitro Hormone Production
Basal progesterone production of midstage CL was higher (P , 0.01) than that of both early and late stages CL, and secretion by late stage CL was higher (P , 0.01) than that of the early ones (Fig. 4, upper panel) . The PPARc agonist 15d-PGJ2 increased (P , 0.01) and the antagonist T0070907 reduced (P , 0.01) in vitro progesterone secretion in early and midluteal stages of pseudopregnancy (Fig. 4, upper panel) .
Basal PGF2a secretion was higher in late CL (P , 0.01) than in the early and midluteal stages, and secretion by midstage CL was higher (P , 0.01) than that of early ones (Fig. 4, middle panel) . The PPARc agonist 15d-PGJ2 reduced (P , 0.01) and the antagonist T0070907 increased (P , 0.01) PGF2a secretion in early and midluteal stages of pseudopregnancy (Fig. 4, middle panel) .
Basal PGE2 secretion was higher in early CL stage (P , 0.01) than in midluteal and late stages, and secretion by late CL stage was higher (P , 0.01) than that of midstage CL (Fig. 4,  lower panel) . Both 15d-PGJ2 and T0070907 did not modify PGE2 in vitro secretion in any luteal stage (Fig. 4, lower  panel) .
Luteal Enzyme Activities
Basal PTGS1 activity was higher in the late CL stage (P , 0.01) than in early and midstages (Fig. 5, upper panel) , whereas PTGS2 activity significantly increased (P , 0.01) with the progress of the CL stages (Fig. 5, middle panel) . Both 15d-PGJ2 and T0070907 did not affect PTGS1 activity in any CL types (Fig. 5, upper panel) , while 15d-PGJ2 reduced (P , 0.01) PTGS2 activity at early stage of pseudopregnancy and T00070907 increased it (P , 0.01) at the midstage (Fig. 5,  middle panel) .
Basal PGE2-9-K activity of late stage CL was higher (P , 0.01) than that of early and midstages, and the activity of midstage CL was higher (P , 0.01) than that of the early ones (Fig. 5, lower panel) . Both 15d-PGJ2 and T0070907 did not affect PGE2-9-K activity in any CL type (Fig. 5, lower panel) .
Basal 3b-HSD activity was higher in midstage CL (P , 0.01) than in early and late stage CL, and activity in late stage CL was lower (P , 0.01) than that of early ones (Fig 6, upper  panel) . The agonist 15d-PGJ2 increased (P , 0.01) and the antagonist T0070907 reduced (P , 0.01) 3b-HSD activity at early and midstages of pseudopregnancy (Fig. 6, upper panel) .
Basal 20a-HSD activity was lower in midstage CL (P , 0.01) than in early and late stage CL, and the activity of late stage CL was higher (P , 0.01) than that of early ones (Fig. 6,  lower panel) . Both 15d-PGJ2 and T0070907 did not affect 20a-HSD activity in any CL types (Fig. 6, lower panel) .
DISCUSSION
The present study provides evidence for the first time of the presence of PPARc in rabbit CL. The results indicate that this nuclear transcription factor may well be another likely candidate for the list of factors known to be involved in luteotropic function.
Several studies have reported the occurrence of PPARc in mammalian ovary; this nuclear receptor has been found in the granulosa and theca cells and also in CL of rodents and ruminants [7, 35, 36] . In addition, PPARc was detected in primary and secondary follicles, being more expressed in the large follicles and decreasing with the LH surge [2, 7, 36] . In bovine CL, PPARc gene and protein expressions increased after ovulation, but decreased if no fertilization or embryo implantation occurred [37, 38] .
Our immunohistochemical results demonstrated the presence of PPARc in the cytoplasm and nuclei of all luteal cells during the three stages of pseudopregnancy examined. Of note, in late stage CL, the majority of nuclei were immunonegative. This finding was partly supported by the results on gene expression; indeed, PCR showed the lowest amounts of PPARc PPARGAMMA FUNCTION IN RABBIT CORPORA LUTEA mRNA in late CL. Even if the protein and gene presence did not necessarily imply a role, results indicate that PPARc has a role in regulating the CL life span. In this context, PPARc tissue-specific deletion in mouse ovary led to a decrease in fertility [5] , and Froment et al. [1] found that PPARc plays a significant role in fertility control, preserving CL function during pregnancy. Komar [2] reported that PPARc activation affects progesterone production by ovarian cells. In particular, 15d-PGJ2, an endogenous activator of PPARc, inhibited the basal and gonadotropin-stimulated progesterone production in human granulosa cells [39] , whereas 15d-PGJ2 and ciglitazone, a synthetic PPARc activator, increased the granulosa cell progesterone secretion in eCG-primed immature rats [36] . Porcine theca and bovine luteal cells also showed an increase of progesterone production after PPARc activation by 15d-PGJ2, ciglitazone, or troglitazone, another synthetic activator, [6, 37] . These studies clearly demonstrate that the effect of PPARc on progesterone synthesis depends on cell type, stage of cell differentiation, stage of the ovarian cycle, and/or animal species [2] .
The present research showed that 15d-PGJ2 induced an increase of progesterone production in early and midluteal stage CL cultured in vitro, whereas the inhibitor T0070907 displayed the opposite effect. In contrast, late stage CL were not affected by 15d-PGJ2 or by T0070907 in vitro treatments. Various studies used thiazolidinediones (TZDs), a class of PPARc activators employed as drugs in diabetes mellitus, to evaluate the effects of this nuclear receptor on the synthesis of ovarian steroid hormones and the expression of many rate- limiting steroidogenic enzymes [3] . In particular, 3b-HSD activity was inhibited by troglitazone in porcine granulosa cells [40] , whereas, other authors argued that TZD treatment did not affect 3b-HSD mRNA levels in porcine granulosa cells and protein concentrations in ovine granulosa cells [41, 42] .
In contrast, our data demonstrated that PPARc affects the 3b-HSD activity because 15d-PGJ2, increased and T007090 diminished the activity of this steroidogenic enzyme in early and midstages CL. It is interesting to note that neither the activator nor the inhibitor of PPARc had any effects on 3b-HSD activity during the late luteal stage. Furthermore, 20a-HSD enzymatic activity was not modified by 15d-PGJ2 or by T0070907 in any luteal stage.
The molecular mechanisms of PPARc in ovarian functions are not well understood, notwithstanding the suggestion that PPARc can directly influence PTGS2 gene expression [1] . In fact, the PTGS2 promoter region contains a PPARc response element [43] . On the other hand, there are conflicting studies that report both PPARc stimulating [40] and inhibiting [44, 45] effects on PTGS2 gene expression.
The present study found evidence for PPARc downregulation of PTGS2 luteal activity at both the early and midstages of pseudopregnancy, as suggested by the coherent effects induced by 15d-PGJ2 and the opposite ones by T0070907. Our data indirectly indicate that this PTGS2 down-regulation may cause a decrease of PGF2a in vitro secretion by early and midstages CL, whereas neither PTGS1 activity nor PGE2 release were modified. In rabbit CL, PGE2-9-K has a modulator role that correlates its enzymatic activity with PGE2 and PGF2a synthesis negatively and positively, respectively [21] . Wintergalen et al. [46] found that in the rabbit, luteal PGE2-9-K also exerts an effect on 20a-HSD catalytic activity, thus favoring the conversion of progesterone into the inactive metabolite 20a-OH-progesterone, with a clear luteolytic effect. Interestingly, these results for 20a-HSD and PPARGAMMA FUNCTION IN RABBIT CORPORA LUTEA PGE2-9-K activity fit with similar findings in the endometrium [47] and placentomes [48] of bovine. As we found for 20a-HSD, PGE2-9-K activity was not modified by 15d-PGJ2 or T0070907 treatments in any luteal stage.
In conclusion, our research found evidence for a possible luteotropic role for PPARc in the pseudopregnant rabbit, with a mechanism that involves the up-regulation of 3b-HSD and the increase of progesterone as well as the down-regulation of the luteolytic factor PGF2a and its correlated enzyme PTGS2 [21] . This hypothetical mechanism is further supported by the clear reduction of the presence of PPARc in the nucleus of luteal cells in late stage4 CL, a reduction that could be required for luteolysis. However, although the present data shed new light on possible PPARc physiological mechanisms regulating luteal activity of mammals, further studies are needed to better understand the fine-tuning of this nuclear receptor in controlling the luteal life span.
